Medication Therapy Management With Pharmacogenetic Testing

Completed · Not applicable

Conditions studied: Pharmacogenetics, Medication Therapy Management

In brief

This study aims to investigate the benefit and feasibility of providing pharmacogenetic (PGx) testing as part of a standard medication therapy management (MTM) session for patients taking multiple medications, a high-risk population for adverse drug reactions and non-response. Research participants will attend two MTM sessions and undergo PGx testing to inform the MTM plan. Participants will also complete 2 surveys pre and post-MTM/PGx testing. Data analysis will assess the impact of MTM/PGx testing on recommendations for drug dosing, clinical outcomes, patient satisfaction, and feasibility of service delivery. Safety issues are minimal with the primary risks being associated with loss of confidentiality, typical discomfort associated with acquiring blood samples, and genetic discrimination.

Key facts

Study ID

NCT01970774

Run by

Duke University

People needed

30

Starts

2013-11-01

Expected to finish

2014-10-01

Last updated by the study team

2015-04-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• currently prescribed 3 medications, one of which must be simvastatin or clopidogrel
• 18 years of age or older
• English speaking
• patients of Mahesh Patel or William Kraus at Duke Southpoint Clinic

You may not qualify if…

• if patient has ever had MTM or PGx

Where it is running

• Duke Health Center at Southpoint — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.